Browsing Tag

Industry Radar

152 posts

The Pharma Pulse: Mergers and Acquisitions
By

By
Mergers and acquisition in the pharmaceutical and life-sciences sector have been a mixed bag in the first half of 2021. The total value and number of deals increased exponentially compared…

Clinical Trial Material Supply: Is Change Coming?
By

By
The COVID-19 pandemic gave rise to innovation in conducting clinical trials, including decentralized and direct-to-patient services. Will this trend continue, and what may be the impact on clinical trial material…

Mid-Year CDMO Review: COVID-19 Vaccine Manufacturing and M&A
By

By
What have been the key developments in 2021 thus far in the CDMO market? Increasing participation by CDMOs in COVID-19 vaccine manufacturing and robust mergers and acquisition activity have marked…

The Pharma Pulse: Small Molecules and Biologics
By

By
How are small molecules & biologics trending among new drug approvals and potential blockbuster drugs? Will biologics overtake small molecules as the leading modality, and if so, in what areas?…

Bio/Pharma R&D Stayed Robust Despite the Pandemic
By

By
Despite significant disruption and reprioritization of clinical trial activity during 2020 due to COVID-19, R&D activity levels remained at historically high levels, driven by new funding and strategic transactions, especially…

The EU’s API Supply Chain Under Focus
By

By
The European Commission has updated the EU’s Industrial Strategy, which was first put forth in March 2020 with goals of realizing a green and digital economy while increasing the EU’s…

COVID-19 and the Bio/Pharma Industry: The Bottom Line
By

By
What has been the impact of COVID-19 on bio/pharmaceutical companies’ bottom line? For companies successfully bringing products for COVID-19 to fruition, 1Q 2021 results have been positive. What is expected…

Into the Future: 3D Printing and Solid Dosage Drugs
By

By
Three-dimensional (3D) printing is an emerging technology across multiple industries, including the bio/pharmaceutical industry. To date, one drug using 3D printing has been approved by the FDA. What’s behind the…

Industry Raises Red Flags Over Drug-Pricing Bill in the US
By

By
The Biotechnology Innovation Organization and the Pharmaceutical Research and Manufacturers of America have raised concerns over recently re-introduced legislation in Congress over drug pricing. The bill includes measures for international…

The EU and Fine Chemicals: What’s Next
By

By
The European Commission took another step to address ways to improve the resilience of the EU’s pharmaceutical manufacturing value chain by issuing a revised roadmap for its Pharmaceutical Strategy for…